Jaber Abdulwahab Asiri, Rami Abdullah Alghamdi, Ahmed Ali AlRizqi, Shahad Khalaf Alrasheed, Abdulaziz Alaythan, Bander Mukhlef Alshammri, Mohammed Abdullah Alshehri, Mohammed Hadi Alarjani, Zyad Alshehri, Nahed Nasser ALFawaz, Rayan Saad Albalawi
{"title":"评估锝- 99m高锝流治疗Graves病的方案：方法学见解：一个病例系列。","authors":"Jaber Abdulwahab Asiri, Rami Abdullah Alghamdi, Ahmed Ali AlRizqi, Shahad Khalaf Alrasheed, Abdulaziz Alaythan, Bander Mukhlef Alshammri, Mohammed Abdullah Alshehri, Mohammed Hadi Alarjani, Zyad Alshehri, Nahed Nasser ALFawaz, Rayan Saad Albalawi","doi":"10.1186/s13256-025-05365-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Graves' disease is the most prevalent cause of hyperthyroidism globally, with technetium-99m pertechnetate widely utilized in its diagnosis. Dynamic scintigraphy using technetium-99m pertechnetate has shown promise for early detection of Graves' disease, particularly in subclinical presentations, but lacks standardized evaluation. This study aims to explore the utility of a dynamic technetium-99m pertechnetate scintigraphy protocol in hyperthyroidism, focusing on its diagnostic advantages and potential clinical applications.</p><p><strong>Case presentation: </strong>The cases described involved adult male and female patients aged 34-40 years of Saudi Middle Eastern ethnicity.</p><p><strong>Conclusions: </strong>Dynamic flow imaging using technetium-99m pertechnetate represents a promising diagnostic approach for Graves' disease, particularly in challenging subclinical cases. This protocol has the potential to refine diagnostic accuracy and guide treatment decisions. Further validation through larger studies is warranted to establish its clinical utility.</p>","PeriodicalId":16236,"journal":{"name":"Journal of Medical Case Reports","volume":"19 1","pages":"297"},"PeriodicalIF":0.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210679/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluating the technetium-99 m pertechnetate flow protocol for Graves' disease: methodological insights: a case series.\",\"authors\":\"Jaber Abdulwahab Asiri, Rami Abdullah Alghamdi, Ahmed Ali AlRizqi, Shahad Khalaf Alrasheed, Abdulaziz Alaythan, Bander Mukhlef Alshammri, Mohammed Abdullah Alshehri, Mohammed Hadi Alarjani, Zyad Alshehri, Nahed Nasser ALFawaz, Rayan Saad Albalawi\",\"doi\":\"10.1186/s13256-025-05365-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Graves' disease is the most prevalent cause of hyperthyroidism globally, with technetium-99m pertechnetate widely utilized in its diagnosis. Dynamic scintigraphy using technetium-99m pertechnetate has shown promise for early detection of Graves' disease, particularly in subclinical presentations, but lacks standardized evaluation. This study aims to explore the utility of a dynamic technetium-99m pertechnetate scintigraphy protocol in hyperthyroidism, focusing on its diagnostic advantages and potential clinical applications.</p><p><strong>Case presentation: </strong>The cases described involved adult male and female patients aged 34-40 years of Saudi Middle Eastern ethnicity.</p><p><strong>Conclusions: </strong>Dynamic flow imaging using technetium-99m pertechnetate represents a promising diagnostic approach for Graves' disease, particularly in challenging subclinical cases. This protocol has the potential to refine diagnostic accuracy and guide treatment decisions. Further validation through larger studies is warranted to establish its clinical utility.</p>\",\"PeriodicalId\":16236,\"journal\":{\"name\":\"Journal of Medical Case Reports\",\"volume\":\"19 1\",\"pages\":\"297\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210679/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13256-025-05365-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13256-025-05365-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Evaluating the technetium-99 m pertechnetate flow protocol for Graves' disease: methodological insights: a case series.
Background: Graves' disease is the most prevalent cause of hyperthyroidism globally, with technetium-99m pertechnetate widely utilized in its diagnosis. Dynamic scintigraphy using technetium-99m pertechnetate has shown promise for early detection of Graves' disease, particularly in subclinical presentations, but lacks standardized evaluation. This study aims to explore the utility of a dynamic technetium-99m pertechnetate scintigraphy protocol in hyperthyroidism, focusing on its diagnostic advantages and potential clinical applications.
Case presentation: The cases described involved adult male and female patients aged 34-40 years of Saudi Middle Eastern ethnicity.
Conclusions: Dynamic flow imaging using technetium-99m pertechnetate represents a promising diagnostic approach for Graves' disease, particularly in challenging subclinical cases. This protocol has the potential to refine diagnostic accuracy and guide treatment decisions. Further validation through larger studies is warranted to establish its clinical utility.
期刊介绍：
JMCR is an open access, peer-reviewed online journal that will consider any original case report that expands the field of general medical knowledge. Reports should show one of the following: 1. Unreported or unusual side effects or adverse interactions involving medications 2. Unexpected or unusual presentations of a disease 3. New associations or variations in disease processes 4. Presentations, diagnoses and/or management of new and emerging diseases 5. An unexpected association between diseases or symptoms 6. An unexpected event in the course of observing or treating a patient 7. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
